Literature DB >> 28940390

Effects of genomic disruption of a guanine quadruplex in the 5' UTR of the Bcl-2 mRNA in melanoma cells.

Tatsuo Serikawa1, Jürgen Eberle2, Jens Kurreck1.   

Abstract

G-quadruplex structures in the 5' UTR of mRNAs have been shown to suppress translation. However, all experiments published so far made use of artificial reporter systems. Here, we investigate for the first time the biological effects of the genomic disruption of a G-quadruplex by CRISPR/Cas9. In melanoma cells lacking the G-quadruplex-forming sequence in the mRNA of the apoptosis inhibitor Bcl-2, the protein level of Bcl-2 remains virtually unchanged. Consequently, sensitivity to an inducer of apoptosis is not reduced. Thus, it is likely that the inhibitory effects of G-quadruplexes observed to date were more pronounced due to the use of the strong overexpression in transfection experiments, whereas G-quadruplexes in endogenous mRNAs, expressed at moderate levels, are widely resolved by cellular RNA helicases.
© 2017 Federation of European Biochemical Societies.

Entities:  

Keywords:  Bcl-2; RNA G-quadruplexes; apoptosis; cancer; melanoma; post-transcriptional regulation; translational regulation

Mesh:

Substances:

Year:  2017        PMID: 28940390     DOI: 10.1002/1873-3468.12855

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

1.  Alternatively spliced variants of the 5'-UTR of the ARPC2 mRNA regulate translation by an internal ribosome entry site (IRES) harboring a guanine-quadruplex motif.

Authors:  Munir A Al-Zeer; Mariola Dutkiewicz; Annekathrin von Hacht; Denise Kreuzmann; Viola Röhrs; Jens Kurreck
Journal:  RNA Biol       Date:  2019-08-14       Impact factor: 4.652

Review 2.  The regulation and functions of DNA and RNA G-quadruplexes.

Authors:  Dhaval Varshney; Jochen Spiegel; Katherine Zyner; David Tannahill; Shankar Balasubramanian
Journal:  Nat Rev Mol Cell Biol       Date:  2020-04-20       Impact factor: 94.444

Review 3.  The histone variant H2A.Z in gene regulation.

Authors:  Benedetto Daniele Giaimo; Francesca Ferrante; Andreas Herchenröther; Sandra B Hake; Tilman Borggrefe
Journal:  Epigenetics Chromatin       Date:  2019-06-14       Impact factor: 4.954

4.  An RNA guanine quadruplex regulated pathway to TRAIL-sensitization by DDX21.

Authors:  Ewan K S McRae; Steven J Dupas; Evan P Booy; Ramanaguru S Piragasam; Richard P Fahlman; Sean A McKenna
Journal:  RNA       Date:  2019-10-25       Impact factor: 4.942

Review 5.  Reversal of G-Quadruplexes' Role in Translation Control When Present in the Context of an IRES.

Authors:  Mohammed Enamul Hoque; Thulasi Mahendran; Soumitra Basu
Journal:  Biomolecules       Date:  2022-02-16

Review 6.  Interaction between non-coding RNAs, mRNAs and G-quadruplexes.

Authors:  Soudeh Ghafouri-Fard; Atefe Abak; Aria Baniahmad; Bashdar Mahmud Hussen; Mohammad Taheri; Elena Jamali; Marcel E Dinger
Journal:  Cancer Cell Int       Date:  2022-04-29       Impact factor: 6.429

7.  Small molecule-based detection of non-canonical RNA G-quadruplex structures that modulate protein translation.

Authors:  Yousuke Katsuda; Shin-Ichi Sato; Maimi Inoue; Hisashi Tsugawa; Takuto Kamura; Tomoki Kida; Rio Matsumoto; Sefan Asamitsu; Norifumi Shioda; Shuhei Shiroto; Yoshiki Oosawatsu; Kenji Yatsuzuka; Yusuke Kitamura; Masaki Hagihara; Toshihiro Ihara; Motonari Uesugi
Journal:  Nucleic Acids Res       Date:  2022-08-12       Impact factor: 19.160

8.  eIF4A alleviates the translational repression mediated by classical secondary structures more than by G-quadruplexes.

Authors:  Joseph A Waldron; Farheen Raza; John Le Quesne
Journal:  Nucleic Acids Res       Date:  2018-04-06       Impact factor: 16.971

9.  RNA G-quadruplexes at upstream open reading frames cause DHX36- and DHX9-dependent translation of human mRNAs.

Authors:  Pierre Murat; Giovanni Marsico; Barbara Herdy; Avazeh T Ghanbarian; Guillem Portella; Shankar Balasubramanian
Journal:  Genome Biol       Date:  2018-12-27       Impact factor: 13.583

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.